Littérature scientifique sur le sujet « Adverse effects/therapeutic use »
Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres
Sommaire
Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Adverse effects/therapeutic use ».
À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.
Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.
Articles de revues sur le sujet "Adverse effects/therapeutic use"
Nahata, Milap C. « Antiviral Drugs : Pharmacokinetics, Adverse Effects, and Therapeutic Use ». Journal of Pharmacy Technology 3, no 3 (mai 1987) : 100–108. http://dx.doi.org/10.1177/875512258700300305.
Texte intégralAttardo, Silvia, Olimpia Musumeci, Daniele Velardo et Antonio Toscano. « Statins Neuromuscular Adverse Effects ». International Journal of Molecular Sciences 23, no 15 (28 juillet 2022) : 8364. http://dx.doi.org/10.3390/ijms23158364.
Texte intégralSpahn, Joseph D., et Alan K. Kamada. « Special Considerations in the Use of Glucocorticoids in Children ». Pediatrics In Review 16, no 7 (1 juillet 1995) : 266–72. http://dx.doi.org/10.1542/pir.16.7.266.
Texte intégralGrbovic, Leposava, et Miroslav Radenkovic. « Therapeutic use of glucocorticoids and immunosuppressive agents ». Srpski arhiv za celokupno lekarstvo 133, Suppl. 1 (2005) : 67–73. http://dx.doi.org/10.2298/sarh05s1067g.
Texte intégralJabbour, Serge A. « The Importance of Reducing Hyperglycemia While Preserving Insulin Secretion—The Rationale for Sodium-coupled Glucose Co-transporter 2 Inhibition in Diabetes ». US Endocrinology 05, no 01 (2009) : 75. http://dx.doi.org/10.17925/use.2009.05.1.75.
Texte intégralSalman, Saad, Sayyed Muhammad Ashhad Halimi et Inzemam Khan. « Olanzapine Use in Schizophrenia and the Modulation of Its Response by Genetic Variations ». Molecular Medicine Communications 2, no 01 (30 juin 2022) : 43–76. http://dx.doi.org/10.55627/mmc.002.001.0038.
Texte intégralSirasanagandla, Srinivasa Rao, Isehaq Al-Huseini, Hussein Sakr, Marzie Moqadass, Srijit Das, Norsham Juliana et Izuddin Fahmy Abu. « Natural Products in Mitigation of Bisphenol A Toxicity : Future Therapeutic Use ». Molecules 27, no 17 (24 août 2022) : 5384. http://dx.doi.org/10.3390/molecules27175384.
Texte intégralHuestis, Marilyn A., Renata Solimini, Simona Pichini, Roberta Pacifici, Jeremy Carlier et Francesco Paolo Busardò. « Cannabidiol Adverse Effects and Toxicity ». Current Neuropharmacology 17, no 10 (13 septembre 2019) : 974–89. http://dx.doi.org/10.2174/1570159x17666190603171901.
Texte intégralSiroka, Z., et Z. Svobodova. « The toxicity and adverse effects of selected drugs in animals – overview ». Polish Journal of Veterinary Sciences 16, no 1 (1 mars 2013) : 181–91. http://dx.doi.org/10.2478/pjvs-2013-0027.
Texte intégralWalczewska, Sylwia, et Agata Wawrzyniak. « N-acetylcysteine in clinical practice – properties, use and adverse effects ». Pediatria i Medycyna Rodzinna 16, no 3 (30 octobre 2020) : 243–46. http://dx.doi.org/10.15557/pimr.2020.0044.
Texte intégralThèses sur le sujet "Adverse effects/therapeutic use"
Miron, Veronique. « The effects of CNS-accessible multiple sclerosis-directed immuno-modulatory therapies on oligodendroglial lineage cells, myelin maintenance, and remyelination / ». Thesis, McGill University, 2008. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=115701.
Texte intégralStatins inhibit the production of cholesterol (concentrated in the myelin membrane) and isoprenoids (post-translational attachments regulating the functions of proteins such as the Rho GTPases). We showed that treatment of human and rodent-derived OPCs with lipophilic statins induced an initial process extension associated with enhanced differentiation and impaired spontaneous migration, whereas prolonged treatment induced process retraction and cell death. Rodent and human mature OLGs demonstrated similar cytoskeletal and survival responses. Chronic simvastatin therapy of mice inhibited remyelination following demyelination induced by the OLG toxin, cuprizone, attributed to a block in OPC differentiation and consequent decrease in mature OLGs. Even fully myelinated animals treated with simvastatin over the long-term demonstrated a decrease in myelin in the brain by maintaining oligodendroglial cells in the pre-OLG state and preventing continual replacement of mature OLGs.
FTY720 is an agonist of G-protein-coupled receptors S1P1, 3, 4, and 5, that are associated with distinct receptor isotype-selective activation of Rho GTPases. In human OPCs, FTY720 could induce initial S1P3/5-dependent process retraction associated with an inhibition of differentiation, and subsequent S1P1-dependent process extension. Mature OLGs showed a dose-dependent cyclic modulation of process extension and retraction was observed over time. Both human OPCs and OLGs were rescued by FTY720 under death-promoting environments. Both cell types also demonstrated a cyclic and reciprocal modulation of S1P1 and S1P5 mRNA levels, reflected in the recurring receptor isotype-dependent functional responses over time. Studies using organotypic cerebellar slice cultures demonstrated that FTY720 did not impact myelin integrity under basal conditions, yet accelerated remyelination following lysolecithin-induced demyelination. Both treatment regimens were associated with an extension of OPC and mature OLG processes.
Our observations demonstrate that drug concentrations used to modulate immune function can have differential dose and time-dependent effects on OPCs, OLGs, as well as on myelin and remyelination processes. Our findings indicate the need to monitor the effects of putative immuno-modulatory therapies on myelin-related processes in MS patients.
Lau, Kai-ming Eric, et 劉繼明. « Write to heal : how cognitive-change-promoting expressive writing may relieve the adverse effects of stressful lifeevents ». Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2007. http://hub.hku.hk/bib/B37596524.
Texte intégralWilchesky, Machelle 1965. « Arrhythmia risk associated with the use of bronchodilators in patients with chronic obstructive pulmonary disease : cohort studies and methodological issues ». Thesis, McGill University, 2008. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=115713.
Texte intégralOur first study cohort consisted of 6,018 adults aged 55 and older, newly treated with bronchodilator medications. We found that new users of both IB and LABA increased the risk of arrhythmia (RR 2.39 [95% CI 1.42-4.05] and (RR 4.55 [95% CI 1.43-14.45] respectively). When the cohort was restricted by excluding subjects who had recently either been hospitalised or experienced an exacerbation, the elevated risk associated with the new use of IB persisted (RR 3.65 [95% CI 1.72-7.74]), an effect was detected with new use of MX (RR 5.17 [95% CI 1.38-19.30]), but there was insufficient power to detect an effect associated with the new use of LABA.
Due to both power issues and the limited availability of LABA within the Saskatchewan data, we replicated the analysis in a larger new-user cohort of 76,661 Quebec adults aged 67 and over. This study confirmed our earlier results, with an elevated risk of arrhythmia associated with the new use of both IB and LABA (RR 1.43 [95% CI 1.08-1.88]) and (RR 1.54 [95% CI 1.00-2.36]) respectively, as well as with new use of SABA (RR 1.28 [95% CI 1.02-1.61]). Finally, using marginal structural models, we demonstrated that both exacerbations of COPD as well as minor non-event arrhythmias were moderate time-dependent confounders within this setting.
In conclusion, we found that new use of bronchodilators in COPD, particularly IB and LABA, was associated with an increase in the risk of cardiac arrhythmias. We also demonstrated the method by which the time-dependent confounder status of specific model covariates may be evaluated.
Belfort, M. A. « The cardiovascular and cerebrovascular effects of laryngoscopy and endotracheal intubation in neonatal piglets, and the modification of these effects by topical lignocaine ». Doctoral thesis, University of Cape Town, 1990. http://hdl.handle.net/11427/26294.
Texte intégralBranco, Klébia Magalhães Pereira Castello. « Análise clínica evolutiva do uso do tacrolimus como droga imunossupressora em transplante cardíaco pediátrico ». Universidade de São Paulo, 2011. http://www.teses.usp.br/teses/disponiveis/5/5131/tde-24052011-163915/.
Texte intégralTacrolimus is a potent calcineurin inhibitor that was introduced in heart transplantation therapy in the early 1990s. Organ transplant recipients with refractory rejection or intolerance to conventional immunosuppressant may respond to rescue therapy with tacrolimus. The aim of this study was to evaluate the clinical outcome of children undergoing heart transplantation who required conversion from a cyclosporine to a tacrolimus-based immunosuppressive regimen due to refractory rejection, late rejection or cyclosporine intolerance. We performed a prospective observational cohort study in 28 children who underwent cardiac transplantation at the Heart Institute (InCor) University of São Paulo Medical School and who required conversion from July 1999 to December 2009. The clinical outcome of the patients was evaluated after tacrolimus conversion. We also compared the patients on tacrolimus to the patients who remained on cyclosporine, and who had undergone heart transplantation during the same period. The mean age at the time of transplantation was 5.3 years and 8.2 years at the time of conversion. The causes of conversion were adverse side effects in 50% of patients, late rejection in 32% and refractory rejection in 18%. The mean time from heart transplant to conversion was 36 months and the mean follow-up period was 74 months. We observed complete resolution of refractory rejection episodes and adverse side effects in all patients. The incidence rate (x100) of rejection episodes before and after conversion was 7.98 and 2.11, respectively (p = <0.0001). The rate of infectious episodes before conversion was 5.89 and after conversion was 4.18 (p = 0.023). There was no statistically significant difference in relation to tumor, renal failure requiring dialysis, systemic arterial hypertension, dyslipidemia, gallstones, diabetes mellitus, anemia, neurological complications, hirsutism and gingival hyperplasia after conversion. A significant incidence of cardiac allograft vasculopathy after conversion to tacrolimus was found (p = 0.004). When comparing patients on tacrolimus to patients on cyclosporine, there was a significant decrease in the incidence of rejection (p = 0.001), and infectious episodes (p = 0.002) in patients using tacrolimus. Patients converted to tacrolimus when compared to patients on cyclosporine had lower neurological complications, hirsutism and gingival hyperplasia, but higher prevalence of anemia. There was a 25% mortality rate in patients using tacrolimus after a mean period of 60 months after conversion. Three deaths were secondary to rejection, and only one in the first year after transplant. Patients using tacrolimus showed greater survival rate when compared to patients taking cyclosporine. The clinical outcome of children undergoing heart transplantation and who required conversion of immunosuppressive regimen allowed us to conclude that tacrolimus is effective as rescue therapy for refractory rejection and is a therapeutic option in pediatric patients
Júnior, Otacílio de Oliveira Maia. « Efeitos do acetonido de triancinolona associado à panfotocoagulação na retinopatia diabética proliferativa ». Universidade de São Paulo, 2008. http://www.teses.usp.br/teses/disponiveis/5/5149/tde-29042008-133531/.
Texte intégralINTRODUCTION: The gold standard treatment for proliferative diabetic retinopahty (PDR) with and without clinically significant macular edema (CSME), as stablished by the Early Treatment Diabetic Retinopathy Study (ETDRS), is panretinal photocoagulation (PRP). This treatment lowers the rate of severe vision loss, but does not increase vision. The aim of this study is to evaluate the efficacy and safety of triamcinolone acetonide associated to PRP for the management of PDR. METHOD: This is a prospective, randomized clinical trial for patients with bilateral and symmetrical PDR who had undergone PRP in both eyes. Patients who had CSME were treated with macular focal photocoagulation on the first episode of the PRP. Intravitreal injection of triamcinolone acetonide (4 mg/0.1 ml) was given to the study eye after the last episode of PRP and the fellow eye was used as control. Follow up was 6 months long. Best-corrected visual acuity (BCVA) using ETDRS charts, central macular thickness and macular volume as measured by the optical coherence tomography software, and the amount of bleeding (both preretinal and vitreous) were the parameters chosen to analyse outcome. Side effects of triamcinolone acetonide such as intraocular pressure, cataracts and severe inflammation, were also followed during the study. RESULTS: Twenty eight diabetes type 2 patients were included. Twenty two study eyes and 23 fellow eyes (controls) presented with CSME (p= 0.317). Mean age was 61.36 ± 5.77 years, with 57.1% females. Many patients had hypertension (82.1%) and used insulin (75.0%). There was no significant difference on the number of spots used for PRP or macular photocoagulation in between the groups. The study eyes had lower BCVA on baseline than the control eyes (p= 0.040). One week after the treatment, there was no difference on BCVA between the study and control eyes. During the follow up, the study group increased their BCVA on the first (p< 0.001), third (p< 0.001) and sixth month (p< 0.001) compared to control. Even thought there was no significant difference on central macular thickness and macular volume between groups on baseline, the study eyes had significant lower measurements on the first week and first, third and sixth months in comparison to controls. Nine control eyes (32.1%) had hemorrhages and none study eyes (p< 0.001). Injected eyes had higher intraocular pressure than controls on the first week of treatment (p< 0.05). None of the eyes developed cataracts that needed surgery, endophthalmits or severe inflammation. CONCLUSION: This study suggests intravitreal injection of triamcinolone is a safe procedure that increases funcional and anatomical prognosis of the macula in PDR eyes that underwent PRP.
Corley, Amanda. « The use of a securement bundle to prevent peripheral intravenous catheter failure ». Thesis, Griffith University, 2022. http://hdl.handle.net/10072/413292.
Texte intégralThesis (PhD Doctorate)
Doctor of Philosophy (PhD)
School of Nursing & Midwifery
Griffith Health
Full Text
Pessotti, Cristiane Felix Ximenes. « Estudo comparativo do uso do antiagregante plaquetário e anticoagulante oral na profilaxia de trombose em pacientes submetidos à operação cavopulmonar total com tubo extracardíaco : análise ecorcardiográfica, angiotomográfica, cintililográfica, laboratorial e clínica ». Universidade de São Paulo, 2013. http://www.teses.usp.br/teses/disponiveis/5/5156/tde-07022014-160413/.
Texte intégralProspective randomized trial of 30 patients who had undergone total cavopulmonary anastomosis via an extracardiac conduit. The data reflect the period between 2008 and 2011, with two-year follow-up, through clinical, laboratorial, echocardiographic, angiotomographic, and scintigraphic assessment. In this study, we aimed to compare the efficiency of ASA (Aspirin) and Warfarin in the preventive treatment of thrombosis in the tried population. For such, we\'ve analyzed changes in coagulation factors (VII, VIII and Protein C) or in the clinical data which would predispose the occurrence of postoperative thrombus. Moreover, during postoperative care, after randomization (15 patients randomly selected to be trated with Warfarin, referred to as Group I, and 15 patients randomly selected to be treated with ASA, referred to as Group II), we also studied the influence of fenestration in the occurrence of thrombus; hemodynamic variations which could contribute to the occurrence of thrombus (slow blood flow in the extracardiac conduit), with postoperative transesophageal echocardiogram being performed within 10 days, and thereafter 3, 6, 12 and 24 months. Besides the echocardiograms aforementioned, the presence of thromboembolic events was sought after by clinical appointments taking place with the same frequency, which evaluated, apart from thromboembolism, side effects or complications from the usage of each of the drugs. We\'ve also evaluated the compliance to and feasibility of each of them. Postoperative angiotomography was also performed during the follow-up, within 6, 12 and 24 months, for the evaluation of changes on the inside wall of the extracardiac conduit, as well as thrombi, and pulmonary ventilation/perfusion scintigraphy for assessment of pulmonary thromboembolism possibility. During the follow-up, two deaths were registered, both in the group being treated with Warfarin. Overall, in the two-year follow-up, 33,3% of the patients presented thromboembolic events. Among the group being treated with ASA, 46,7% presented such complication, whereas in the group being treated with Warfarin, 20% had the same complication (p=0,121). Regarding the preoperative evaluation, prior occurrence of thrombus and low levels of coagulation factor Protein C were the only variables which influenced living time without thrombus, with p-values of 0,035 and 0,047. At the end of the two-year follow-up, in the angiotomographic evaluation, 35,7% of patients treated with ASA presented material accumulation inside the extracardiac conduit, with over 2mm of thickness (p=0,082). As for the ventilation/perfusion scintigraphy, two patients presented traces of pulmonary thromboembolism, both treated with ASA (p=0,483), one of whom with unfavorable development of the Fontan circuit. Concerning safety and compliance to the treatment, five patients had difficulty to comply with the treatment (only viable for its trial nature), among those, four under treatment with Warfarin and presenting INR values ranging from 1 to 6,4. For quantitative verification, providing statistic value to the data, an effort must be made for a larger number of patients to be gathered and tried with this treatment. However, the difference in results concerning thrombus-free recovery between the two groups during the two years following surgery cannot, and must not, be ignored
Sauer, Herbert. « Tratamento transureteroscópico do cálculo ureteral com HOLMIUM : YAG laser ». Universidade de São Paulo, 2004. http://www.teses.usp.br/teses/disponiveis/5/5153/tde-19032007-104915/.
Texte intégralObjetive: Holmium:YAG laser is the more recently method of intracorporeal lithotripsy of urinary calculi introduced in our area. The purpose of this study is to analyze the technique and to evaluate the immediate results and complications in the treatment of patients with ureteral calculi. Casuistry and Methods: Sixteen patients were treated, nine men and seven women, carrying symptomatic ureteral stones, bigger than 6 mm or with evolution superior to 30 days. The average age was 42 years old (6-88 years old). Four stones were localized in upper ureter, six in middle ureter, and six in lower ureter. The technique employed was the vaporization of the stone with Holmium:YAG laser, through ureteroscopy. It was used exclusively 7-Fr semirigid ureteroscope. Results: The rate of success attained was of 87.5%, with no statistically significant differences regarding the reports in literature. All the stones were fragmented. The two failures of the series occurred with stones localized in upper ureter, in which fragments were displaced to kidney. The complications observed were three ureteral perforations and two fever cases. Conclusion: Holmium:YAG laser is effective in the endoscopic treatment of ureteral stones. Measures aimed at preventing retrograde migration of stones or fragments should be taken, mainly when the stone are located in the upper ureter. However, lithotripsy with Holmium:YAG laser may be associated with complications, particularly in what concerns the treatment of impacted stones.
Szabó, Zoltán. « Diabetes and coronary surgery : metabolic and clinical studies on diabetic patients after coronary surgery with special reference to cardiac metabolism and high-dose GIK / ». Linköping : Univ, 2001. http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-5219.
Texte intégralLivres sur le sujet "Adverse effects/therapeutic use"
Aspirin : Therapeutic uses, adverse effects, and pharmacokinetics. Hauppauge, N.Y : Nova Science Publishers, 2011.
Trouver le texte intégralTvildiani, Djavakhi, et Kakha Gegechkori. Opioids : Pharmacology, clinical uses and adverse effects. New York : Nova Science Publishers, Inc., 2012.
Trouver le texte intégralJ, McLean Michael, Engström Stefan et Holcomb Robert R. 1940-, dir. Magnetotherapy : Potential therapeutic benefits and adverse effects. New York, NY : TFG Press, 2003.
Trouver le texte intégralUnited States. Agency for Healthcare Research and Quality, dir. Garlic : Effects on cardiovascular risks and disease, protective effects against cancer, and clinical adverse effects. [Rockville, Md : Agency for Healthcare Research and Quality, 2000.
Trouver le texte intégralUnited States. Agency for Healthcare Research and Quality, dir. Milk thistle : Effects on liver disease and cirrhosis and clinical adverse effects. [Rockville, Md : Agency for Healthcare Research and Quality, 2000.
Trouver le texte intégralI, Quinn Paul, dir. Aspirin and health research progress. New York : Nova Science Publishers, 2008.
Trouver le texte intégralZimmerman, Roy. Adverse effects of lithium : Medical subject analysis with reference bibliography. Washington, D.C : ABBE Publishers Association, 1987.
Trouver le texte intégralPhenylpropanolamine : A critical analysis of reported adverse reactions and overdosage. Fort Lee, N.J : J.K. Burgess, 1986.
Trouver le texte intégralFischer, Leoni M. Brachytherapy : Types, dosing, and side effects. Hauppauge, N.Y : Nova Science Publishers, 2010.
Trouver le texte intégralSteroids. Santa Barbara, California : Greenwood, 2014.
Trouver le texte intégralChapitres de livres sur le sujet "Adverse effects/therapeutic use"
Frye, Richard Eugene, James P. Andrus, Kevin V. Lemley, Stephen C. De Rosa, Pietro Ghezzi, Arne Holmgren, Dean Jones et al. « Pharmacology, Formulations, and Adverse Effects ». Dans The Therapeutic Use of N-Acetylcysteine (NAC) in Medicine, 387–94. Singapore : Springer Singapore, 2018. http://dx.doi.org/10.1007/978-981-10-5311-5_21.
Texte intégralBossi, Paolo, et Luigi Lorini. « Optimal Supportive Measures during Primary Treatment ». Dans Critical Issues in Head and Neck Oncology, 221–30. Cham : Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-63234-2_15.
Texte intégralFrohns, A., et F. Frohns. « Safety of Water-Filtered Infrared A (wIRA) on the Eye as a Novel Treatment Option for Chlamydial Infections ». Dans Water-filtered Infrared A (wIRA) Irradiation, 259–69. Cham : Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-92880-3_22.
Texte intégralKim, Suck Won, et Jon E. Grant. « Electroconvulsive Therapy : Indications, Use and Adverse Effects ». Dans The Medical Basis of Psychiatry, 919–24. New York, NY : Springer New York, 2016. http://dx.doi.org/10.1007/978-1-4939-2528-5_41.
Texte intégralNeubert, Diether, Robert J. Kavlock, Hans-Joachim Merker et Jane Klein. « General Discussion : Use of Biologically Based Models ». Dans Risk Assessment of Prenatally-Induced Adverse Health Effects, 289–90. Berlin, Heidelberg : Springer Berlin Heidelberg, 1992. http://dx.doi.org/10.1007/978-3-642-77753-0_22.
Texte intégralBasu, T. K. « Possible Adverse Effects of the Pharmacological Use of Vitamins ». Dans Drug∼Nutrient Interactions, 92–106. Dordrecht : Springer Netherlands, 1988. http://dx.doi.org/10.1007/978-94-011-7081-9_5.
Texte intégralFernández, Xavier, Rafael Guimarães dos Santos, Marta Cutchet, Sabela Fondevila, Débora González, Miguel Ángel Alcázar, Jordi Riba, José Carlos Bouso et Josep María Fábregas. « Assessment of the Psychotherapeutic Effects of Ritual Ayahuasca Use on Drug Dependency : A Pilot Study ». Dans The Therapeutic Use of Ayahuasca, 183–96. Berlin, Heidelberg : Springer Berlin Heidelberg, 2013. http://dx.doi.org/10.1007/978-3-642-40426-9_11.
Texte intégralSchmid, Janine Tatjana. « Healing with Ayahuasca : Notes on Therapeutic Rituals and Effects in European Patients Treating Their Diseases ». Dans The Therapeutic Use of Ayahuasca, 77–93. Berlin, Heidelberg : Springer Berlin Heidelberg, 2013. http://dx.doi.org/10.1007/978-3-642-40426-9_5.
Texte intégralDuffus, John H., et Morrell H. Draper. « Approaches to Identifying Adverse Health Effects of Chemicals in Use ». Dans Chemical Safety, 459–84. Weinheim, Germany : VCH Verlagsgesellschaft mbH, 2007. http://dx.doi.org/10.1002/9783527616039.ch30.
Texte intégralMead, Phillip G. « Assessment of Design Configurations for the Therapeutic use of Daylight ». Dans Biologic Effects of Light 2001, 75–82. Boston, MA : Springer US, 2002. http://dx.doi.org/10.1007/978-1-4615-0937-0_6.
Texte intégralActes de conférences sur le sujet "Adverse effects/therapeutic use"
Soares, Mariana, Ana Clara Mota Gonçalo, Kaline dos Santos Kishishita Castro et Victoria de Menezes Sá Lazera. « Use of cannabidiol as a therapeutic method in epilepsy ». Dans XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.388.
Texte intégralSeixas, Júlia Maia, Hygor Kleber Cabral Silva, Maria Alice Rocha Lopes, Kamila Castro Oliveira Camargos, Lara Silveira Marques, Maria Tereza Nogueira Fonseca e. Souza, Bianca Henriques Parreiras, Alice Carvalho Hoffmann et Letícia Fernanda Saraiva Jardim. « Phytocannabinoids use in Alzheimer’s disease ». Dans XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.671.
Texte intégralFigueiredo, Camila Angelo Vidal de, Kaline dos Santos Kishishita Castro et Sílvia Raimunda Costa Leite. « Therapeutic management of movement disorders present in Huntington’s Disease : a literature review ». Dans XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.430.
Texte intégralPereira, Camila Nakamura Perissê, Lamys Fernandes Kozak, Victor Fernandes Feitosa Braga, Pedro Henrique Bersan de Menezes et Alexandre Sampaio Rodrigues Pereira. « The use of erenumab for preventing migraine ». Dans XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.191.
Texte intégralGabrielli, Ângelo, Camila Sousa Bragunce Alves, Bruna Oliveira Bicalho et Débora Pimenta Alves. « Benefits and Challenges of Cannabis Use in the Treatment of Refractory Epilepsy ». Dans XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.239.
Texte intégralAimufua, G. I. O., N. P. Onyechi et U. A. Muhammad. « Development of Anti- Polypharmacy Management System. » Dans 28th iSTEAMS Multidisciplinary Research Conference AIUWA The Gambia. Society for Multidisciplinary and Advanced Research Techniques - Creative Research Publishers, 2021. http://dx.doi.org/10.22624/aims/isteams-2021/v28p14.
Texte intégralĐurđić, Tamara. « ODGOVORNOST ZA ŠTETU OD LEKOVA ». Dans XV Majsko savetovanje : Sloboda pružanja usluga i pravna sigurnost. University of Kragujevac, Faculty of Law, 2019. http://dx.doi.org/10.46793/xvmajsko.667dj.
Texte intégralSantos, Nathalia Lima Schramm dos, William Wallace dos Santos Silva, Geovanna da Silva Campos Conceição, Gabriel Serra Almeida, Jacqueline Oliveira Freitas, Breno Silva Reis et Lucas Santos Silva. « CGRP antagonists : Perspectives on migraine prophylaxis ». Dans XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.193.
Texte intégralChentsova, Victoria, Adrian Bravo et Emily Norton. « From Adverse Childhood Experiences to Problematic Marijuana Use : Examining the Role of Distress Tolerance and Coping Motives on Negative Marijuana Use Consequences ». Dans 2022 Annual Scientific Meeting of the Research Society on Marijuana. Research Society on Marijuana, 2022. http://dx.doi.org/10.26828/cannabis.2022.02.000.13.
Texte intégralSouza, Ellen Lelis de, Marianna Tonaco Silva, Marianne Morais de Pinho da Fonseca et Wanderson Stewart Parreira Miranda. « Integrative review, XIII Paulista Congress of Neurology, May 2021 ; São Paulo (SP). Efficacy of cannabidiol in improving the quality of life of Parkinson´s Patient ; ITPAC-Palmas (TO) ; 2021 ». Dans XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.109.
Texte intégralRapports d'organisations sur le sujet "Adverse effects/therapeutic use"
Cabrera, Anahi Maldonado, Blayra Maldonado Cabrera, Dalia Isabel Sánchez Machado et Jaime López Cervantes. Wound healing therapeutic effect of chitosan nanofibers : a systematic review and meta- analysis of animal studies. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, octobre 2022. http://dx.doi.org/10.37766/inplasy2022.10.0121.
Texte intégralFitzpatrick, Daniel T. Human Factors of Night Vision Device Use in Southwest Asia : Reports of Sensory Illusions and Other Adverse Effects. Fort Belvoir, VA : Defense Technical Information Center, janvier 1992. http://dx.doi.org/10.21236/ada372962.
Texte intégralHernández, Juan. Open configuration options Selection Advantage of Corporate Venture Capitalists and Its Welfare Effects. Inter-American Development Bank, février 2022. http://dx.doi.org/10.18235/0003983.
Texte intégralChou, Roger, Jesse Wagner, Azrah Y. Ahmed, Ian Blazina, Erika Brodt, David I. Buckley, Tamara P. Cheney et al. Treatments for Acute Pain : A Systematic Review. Agency for Healthcare Research and Quality (AHRQ), décembre 2020. http://dx.doi.org/10.23970/ahrqepccer240.
Texte intégralMcDonagh, Marian S., Jesse Wagner, Azrah Y. Ahmed, Benjamin Morasco, Devan Kansagara et Roger Chou. Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain : May 2021 Update. Agency for Healthcare Research and Quality (AHRQ), juin 2021. http://dx.doi.org/10.23970/ahrqepccerplantpain3.
Texte intégralMcDonagh, Marian S., Jesse Wagner, Azrah Y. Ahmed, Rongwei Fu, Benjamin Morasco, Devan Kansagara et Roger Chou. Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain. Agency for Healthcare Research and Quality (AHRQ), octobre 2021. http://dx.doi.org/10.23970/ahrqepccer250.
Texte intégralChou, Roger, Jesse Wagner, Azrah Y. Ahmed, Benjamin J. Morasco, Devan Kansagara, Shelley Selph, Rebecca Holmes et Rongwei Fu. Living Systematic Review on Cannabis and Other Plant-Based Treatments for iii Chronic Pain : 2022 Update. Agency for Healthcare Research and Quality (AHRQ), septembre 2022. http://dx.doi.org/10.23970/ahrqepccer250update2022.
Texte intégralChou, Roger, Azrah Y. Ahmed, Christina Bougatsos, Benjamin J. Morasco, Rebecca Holmes, Terran Gilbreath et Rongwei Fu. Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain : 2022 Update—Surveillance Report 2. Agency for Healthcare Research and Quality (AHRQ), janvier 2023. http://dx.doi.org/10.23970/ahrqepccer250.2022updatesr2.
Texte intégralWiley, Jenny L., Camille K. Gourdet et Brian F. Thomas. Cannabidiol : Science, Marketing, and Legal Perspectives. RTI Press, avril 2020. http://dx.doi.org/10.3768/rtipress.2020.op.0065.2004.
Texte intégralDuan, Liyang, Xiaoyu Li, Haiqin Rong, Haiju Sun, Yajun Zhang, Shipeng Song, Jianqiao Fang et Yongqiang Sun. Scalp acupuncture for Post-stroke depression : A protocol for a systematic review and meta-analysis of randomized controlled clinical trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, avril 2022. http://dx.doi.org/10.37766/inplasy2022.4.0059.
Texte intégral